Brief: PYC Therapeutics Says FDA Granted RPD Designation To Drug Development Program
30/08/2024 02:11
Aug 30 (Reuters) - PYC Therapeutics Ltd PYC.AX :
* FDA GRANTS RARE PEDIATRIC DISEASE DESIGNATION TO PYC DRUG
DEVELOPMENT PROGRAM
Source text for Eikon: ID:nASXgxBTK
Further company coverage: PYC.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on PYC Therapeutics
See all newsAustralia's PYC Therapeutics rises on EU orphan drug status
Brief: PYC Therapeutics Posts HY Revenues From Ordinary Activities A$11.0 Million
Brief: PYC Therapeutics Announces Raising Up To A$653 Million
Brief: PYC Therapeutics Seeks Trading Halt
Brief: PYC Therapeutics Says Rohan Hockings Re-Appointed As Managing Director